I’ve been holding Syngene International for about 3 years now and currently sitting at roughly 36% loss. Today the stock corrected another ~10%, which honestly has shaken my conviction.
When I entered, Syngene was widely considered a strong CRDMO / quasi-monopoly play, backed by Biocon, long client relationships, and structural outsourcing tailwinds in pharma R&D. The expectation was steady, compounding growth over time.
However, the actual stock performance has been quite disappointing:
- Prolonged underperformance vs index
- Valuation derating
- Growth visibility seems patchy
I’m trying to understand:
Has the original Syngene thesis broken?
Is this just a temporary phase (US biotech slowdown, client delays, capex cycle), or are there structural issues?
Do you see Syngene regaining growth momentum over the next 3–5 years, or has the market permanently reassessed it?
Would really appreciate insights.
Thanks in advance.